ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harvey Pass
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pass, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pass, H.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2004;77:1161-1162
© 2004 The Society of Thoracic Surgeons

Invited commentary

Harvey Pass, MD

Division of Cardiothoracic Surgery Karmanos Cancer Institute/Wayne State Suite 2102 Harper Prof Bldg 3990 John R Detroit, MI 48201, USA

e-mail: hpass@dmc.org

The first 20% of the full text of this article appears below.

The manuscript by Sakao and colleagues further emphasizes the need for thoracic surgeons to catch up with technology and biology in the management of lung cancer, and elegantly combines both of these elements. We all keep on trying to define a novel marker of prognostication or early detection with incredibly expensive technologies including gene expression arrays and proteomic expression profiles; however, maybe it is time (in the interim while a multitude of laboratories try to validate new markers) to step back . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.